Read by QxMD icon Read

Macrolide AND pneumonia

Eun-Ae Yang, Kyung-Yil Lee
No abstract text is available yet for this article.
August 2017: Korean Journal of Pediatrics
Konstantinos Z Vardakas, Kyriakos K Trigkidis, Katerina N Apiranthiti, Matthew E Falagas
SCOPE: To study the factors associated with mortality in hospitalized patients with community acquired pneumonia (CAP) treated with monotherapy or combination therapy. METHODS: PubMed and Scopus were searched. Patients receiving macrolides, β-lactams and fluoroquinolones, as monotherapy or in combination were included. Meta-analyses and meta-regressions were performed. RESULTS: Fifty four studies were included. Monotherapy was not associated with higher mortality than combination (RR 1...
October 13, 2017: European Journal of Clinical Investigation
David Haefliger, Christian Chuard
Legionellosis refers to the two clinical syndromes caused by Legionella : Pontiac fever, a benign febrile illness and Legionnaires'disease (or pneumonia). Clinically and radiologically, Legionnaires'disease presents itself as a « typical » pneumonia caused by Streptococcus pneumonia. Diagnosis is usually made by using urinary antigen testing. Culture and PCR are also helpful. Legionella is resistant to betalactam antibiotics, and is treated by quinolones or macrolides.
October 11, 2017: Revue Médicale Suisse
Masato Tashiro, Kiyohide Fushimi, Kei Kawano, Takahiro Takazono, Tomomi Saijo, Kazuko Yamamoto, Shintaro Kurihara, Yoshifumi Imamura, Taiga Miyazaki, Katsunori Yanagihara, Hiroshi Mukae, Koichi Izumikawa
Background: Mycoplasma pneumoniae strains with resistance to macrolides have been spreading worldwide. This study aimed to clarify which antimicrobial agent is a better treatment for patients with M. pneumoniae pneumonia in a setting with large epidemics of macrolide-resistance. Methods: Adult patients hospitalized with laboratory-confirmed M. pneumoniae pneumonia from 2010 to 2013 were identified from the Diagnosis Procedure Combination database, a national database in Japan...
August 16, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Sara Giordana Rimoldi, Bernardina Gentile, Cristina Pagani, Annamaria Di Gregorio, Anna Anselmo, Anna Maria Palozzi, Antonella Fortunato, Valentina Pittiglio, Anna Lisa Ridolfo, Maria Rita Gismondo, Giuliano Rizzardini, Florigio Lista
BACKGROUND: The emergence of carbapenem-resistant Klebsiella pneumoniae strains is threatening antimicrobial treatment. METHODS: Sixty-eight carbapenemase-producing K. pneumoniae strains isolated at Luigi Sacco University Hospital-ASST Fatebenefratelli Sacco (Milan, Italy) between 2012 and 2014 were characterised microbiologically and molecularly. They were tested for drug susceptibility and carbapenemase phenotypes, investigated by means of repetitive extra-genic palindromic polymerase chain reaction (REP-PCR), and fully sequenced by means of next-generation sequencing for the in silico analysis of multi-locus sequence typing (MLST), their resistome, virulome and plasmid content, and their core single nucleotide polymorphism (SNP) genotypes...
October 10, 2017: BMC Infectious Diseases
Yu Suzuki, Yoshitaka Shimotai, Tsutomu Itagaki, Junji Seto, Tatsuya Ikeda, Kazue Yahagi, Katsumi Mizuta, Seiji Hongo, Yoko Matsuzaki
PURPOSE: To determine the timing of the emergence of macrolide-resistant mutations after macrolide treatment in individuals with Mycoplasma pneumoniae infections. METHODOLOGY: Between October 2011 and December 2013, serial pharyngeal swab specimens were collected before and after macrolide treatment from 21 otherwise healthy children infected with M. pneumoniae without macrolide-resistant mutations. The copy numbers of a M. pneumoniae gene and the proportion of clones showing macrolide-resistance mutations were determined for each specimen...
October 6, 2017: Journal of Medical Microbiology
F Jacobs
Lower respiratory tract infections represent one of the main causes of mortality in the world. They essentially consist of bronchitis, acute exacerbations of chronic obstructive bronchopulmonary diseases (COPD) and acute pneumonia. If acute bronchitis is mainly of viral origin, acute exacerbations of COPD and pneumonia are mainly due to a trio of bacteria (Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis). Other pathogens as many viruses and atypical bacteria such as Mycoplasma pneumoniae, Legionella, some Enterobacteriaceae and very rarely Pseudomonas aeruginosa are also implicated...
2017: Revue Médicale de Bruxelles
Frances S Grudzinska, Davinder Ps Dosanjh, Dhruv Parekh, Rachel Ca Dancer, Jaimin Patel, Peter Nightingale, Georgia M Walton, Elizabeth Sapey, David R Thickett
Community-acquired pneumonia (CAP) is the leading cause of death from infection in developed countries. There is evidence of an association between improved survival from infection and statin use. The possible beneficial effects of statins are complicated by the common use of macrolide antibiotics for pneumonia, with current guidance suggesting that concurrent macrolide and statin use is contraindicated.We conducted an observational study of statin use in patients with CAP. Of 2,067 patients with CAP, 30.4% were on statin therapy at admission...
October 2017: Clinical Medicine: Journal of the Royal College of Physicians of London
R K Flamm, P R Rhomberg, H S Sader
Nafithromycin (WCK 4873), a novel antimicrobial agent of the lactone ketolide class, is currently in Phase 2 development for treatment of community-acquired bacterial pneumonia (CABP): A total of 4,739 non-duplicate isolates were selected from a 2014 global surveillance program from medical institutions located in 43 countries within the United States, Europe, Latin America, and Asia-Pacific. Nafithromycin and comparator agents were susceptibility tested by reference broth microdilution methods. Nafithromycin was active against Staphylococcus aureus (MIC50/90, 0...
October 2, 2017: Antimicrobial Agents and Chemotherapy
Adamantia Liapikou, Catia Cillóniz, Antoni Torres
Community acquired pneumonia is one of the main infections, remaining as a global cause of considerable morbidity and mortality. Successful treatment hinges on expedient delivery of appropriate antibiotic therapy tailored to both the likely pathogens and the severity of disease. Although antibiotic resistance is increasing and pharmaceutical companies continue to debate the profitability of introducing new antibacterial agents, an encouraging number of new molecules have recently been unveiled which target multidrug-resistant bacteria...
November 2017: Expert Opinion on Investigational Drugs
R Kogoj, M Praprotnik, T Mrvič, M Korva, D Keše
Two nationwide Mycoplasma pneumoniae epidemics occurred in Slovenia between 2006 and 2016. The aim of this study was to assess which M. pneumoniae genotypes were present in our area during the selected timeframe, whether the origin of the epidemics was monoclonal or polyclonal and whether the proportion between detected genotypes changed over time. We were also interested in the presence of macrolide resistance (MR) and whether it could be linked to specific genotypes. We performed pyrosequencing of the P1 gene and multiple-locus variable-number tandem repeat (VNTR) analysis (MLVA) typing from 872 M...
September 26, 2017: European Journal of Clinical Microbiology & Infectious Diseases
Mark L Metersky, Aruna Priya, Eric M Mortensen, Peter K Lindenauer
BACKGROUND: Many patients hospitalized with pneumonia are treated with combination macrolide/cephalosporin therapy. Macrolides have immunomodulatory effects and do not directly cause bacterial lysis. These effects suggest the possibility that initial treatment with a macrolide before a cephalosporin could improve patient outcomes by preventing the inflammatory response to rapid bacterial lysis that can be caused by cephalosporin treatment. This study explores whether initial treatment for pneumonia with a macrolide before a cephalosporin is associated with better patient outcomes than treatment with a cephalosporin before a macrolide...
2017: Open Forum Infectious Diseases
Takaaki Tanaka, Tomohiro Oishi, Ippei Miyata, Shoko Wakabayashi, Mina Kono, Sahoko Ono, Atsushi Kato, Yoko Fukuda, Aki Saito, Eisuke Kondo, Hideto Teranishi, Yuhei Tanaka, Tokio Wakabayashi, Hiroto Akaike, Satoko Ogita, Naoki Ohno, Takashi Nakano, Kihei Terada, Kazunobu Ouchi
We evaluated isolates obtained from children with Mycoplasma pneumoniae infection throughout Japan during 2008-2015. The highest prevalence of macrolide-resistant M. pneumoniae was 81.6% in 2012, followed by 59.3% in 2014 and 43.6% in 2015. The prevalence of macrolide-resistant M. pneumoniae among children in Japan has decreased.
October 2017: Emerging Infectious Diseases
J M Pereira, J Gonçalves-Pereira, O Ribeiro, J P Baptista, F Froes, J A Paiva
Antibiotic therapy (AT) is the cornerstone of the management of severe community-acquired pneumonia (CAP). However, the best treatment strategy is far from being established. To evaluate the impact of different aspects of AT on the outcome of critically ill patients with CAP, we performed a post hoc analysis of all CAP patients enrolled in a prospective, observational, multicentre study. Of the 502 patients included, 76% received combination therapy, mainly a β-lactam with a macrolide (80%). AT was inappropriate in 16% of all microbiologically documented CAP (n=177)...
September 4, 2017: Journal of Critical Care
Max R Schroeder, Scott T Chancey, Stephanie Thomas, Wan-Hsuan Kuo, Sarah W Satola, Monica M Farley, David S Stephens
Background: Macrolide efflux encoded by mef(E)/mel and ribosomal methylation encoded by erm(B) confer most macrolide resistance in Streptococcus pneumoniae. Introduction of the heptavalent pneumococcal conjugate vaccine (PCV7) in 2000 reduced macrolide-resistant invasive pneumococcal disease (MR-IPD) due to PCV7 serotypes (6B, 9V, 14, 19F, and 23F). Methods: In this study, the impact of PCV7 and PCV13 on MR-IPD was prospectively assessed. A 20-year study of IPD performed in metropolitan Atlanta, Georgia, using active, population-based surveillance formed the basis for this study...
September 15, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Xiaoguang He, Mingyu Xie, Siping Li, Junqin Ye, Qi Peng, Qiang Ma, Xiaomei Lu, Baimao Zhong
BACKGROUND: Bacterial pathogens are a major cause of childhood community acquired lower respiratory tract infections (CA-LRTIs), and few data described the impact of antimicrobial resistance on children with CA-LRTIs. This study aims to investigate the antimicrobial resistance in common bacterial agents among hospitalized children with CA-LRTIs between 2011 and 2016 in Dongguan, China. METHODS: Sputum samples were collected from hospitalized children (0-5 years old) with CA-LRTIs in Dongguan Children's Hospital...
September 11, 2017: BMC Infectious Diseases
David G Bundy, Troy E Richardson, Matthew Hall, Jean L Raphael, David C Brousseau, Staci D Arnold, Ram V Kalpatthi, Angela M Ellison, Suzette O Oyeku, Samir S Shah
Importance: Acute chest syndrome (ACS) is a common, serious complication of sickle cell disease (SCD) and a leading cause of hospitalization and death in both children and adults with SCD. Little is known about the effectiveness of guideline-recommended antibiotic regimens for the care of children hospitalized with ACS. Objectives: To use a large, national database to describe patterns of antibiotic use for children with SCD hospitalized for ACS and to determine whether receipt of guideline-adherent antibiotics was associated with lower readmission rates...
September 11, 2017: JAMA Pediatrics
Aran Singanayagam, Stefano Aliberti, Catia Cillóniz, Antoni Torres, Francesco Blasi, James D Chalmers
International guidelines including those in the UK, Japan, Australia and South Africa recommend the avoidance of macrolides in patients with low-severity community-acquired pneumonia (CAP). We hypothesised that severity scores are poor predictors of atypical pneumonia and response to macrolide therapy, and thus, inadequate tools for guiding antibiotic prescriptions.Secondary analysis of four independent prospective CAP datasets was conducted. The predictive values of the CURB-65 and pneumonia severity index (PSI) for clinically important groups of causative pathogens were evaluated...
September 2017: European Respiratory Journal: Official Journal of the European Society for Clinical Respiratory Physiology
W X Shi, S S Wu, C Gong, A H Li, F Huang
Objective: To analyze the prevalence and drug resistance of mycoplasma pneumoniae in patients with community-acquired pneumonia during 2011-2015 in Beijing. Methods: Totally 2 272 mycoplasma pneumoniae samples were collected from patients with community-acquired pneumonia in 5 sentinel hospitals during 2011-2015. Mycoplasma pneumoniae were detected by real-time PCR. 142 copies of positive samples with Ct value under 30 were cultured to get the strains so that the genotypes based on the P1 gene sequence and the drug resistance based on the in vitro drug resistance test could be conducted...
September 6, 2017: Zhonghua Yu Fang Yi Xue za Zhi [Chinese Journal of Preventive Medicine]
Yoon Joo Kim, Kyung Sue Shin, Keun Hwa Lee, Young Ree Kim, Jae Hong Choi
Mycoplasma pneumoniae is the major pathogen of community-acquired pneumonia in children. The prevalence of macrolide-resistant M. pneumoniae (MRMP) is important owing to the limited alternative therapies for children. We analyzed 111 M. pneumoniae obtained from 107 children admitted for lower respiratory tract infection at Jeju National University Hospital between 2010 and 2015. Macrolide resistance of M. pneumoniae was searched for using polymerase chain reaction (PCR) and sequencing. Of 107 clinical M. pneumoniae, 11 (10...
October 2017: Journal of Korean Medical Science
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"